Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Given Average Rating of “Hold” by Brokerages

Shares of Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) have been given an average recommendation of “Hold” by the eight analysts that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $36.50.

LKFT has been the topic of several recent analyst reports. UBS Group reissued a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research note on Tuesday, February 24th. Raymond James Financial reaffirmed a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research note on Tuesday, February 24th. Wall Street Zen cut shares of Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Zacks Research cut shares of Lakefront Biotherapeutics American Depositary Shares from a “hold” rating to a “strong sell” rating in a report on Friday, May 8th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a report on Tuesday, May 26th.

Lakefront Biotherapeutics American Depositary Shares Stock Up 0.9%

Shares of LKFT stock opened at $27.51 on Thursday. The business has a 50 day moving average of $28.42 and a two-hundred day moving average of $31.27. Lakefront Biotherapeutics American Depositary Shares has a 52 week low of $26.42 and a 52 week high of $37.78. The company has a market cap of $1.81 billion, a P/E ratio of -19.51 and a beta of 0.26.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last issued its earnings results on Sunday, February 15th. The biotechnology company reported $13.92 EPS for the quarter. The company had revenue of $1.06 billion during the quarter. Analysts expect that Lakefront Biotherapeutics American Depositary Shares will post -6.32 EPS for the current fiscal year.

Institutional Investors Weigh In On Lakefront Biotherapeutics American Depositary Shares

Several hedge funds have recently made changes to their positions in LKFT. Bank of America Corp DE increased its holdings in shares of Lakefront Biotherapeutics American Depositary Shares by 2.1% during the third quarter. Bank of America Corp DE now owns 30,949 shares of the biotechnology company’s stock worth $1,072,000 after buying an additional 643 shares in the last quarter. Van ECK Associates Corp increased its holdings in shares of Lakefront Biotherapeutics American Depositary Shares by 61.6% in the fourth quarter. Van ECK Associates Corp now owns 1,968 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 750 shares in the last quarter. Two Sigma Investments LP increased its holdings in shares of Lakefront Biotherapeutics American Depositary Shares by 3.7% in the third quarter. Two Sigma Investments LP now owns 22,459 shares of the biotechnology company’s stock valued at $778,000 after purchasing an additional 800 shares in the last quarter. State of Wyoming acquired a new stake in Lakefront Biotherapeutics American Depositary Shares during the 2nd quarter worth $28,000. Finally, Arax Advisory Partners grew its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 319.2% during the fourth quarter. Arax Advisory Partners now owns 2,335 shares of the biotechnology company’s stock worth $76,000 after purchasing an additional 1,778 shares during the period. Institutional investors own 32.46% of the company’s stock.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.